Angiogenic effects of erythropoietin

International Review of Cell and Molecular Biology

Volumn 299, Issue , 2012, Pages 199-234

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Antiangiogenesis; Cardiovascular system; Erythropoietin; Hypoxia; Tumor growth

Indexed keywords

ANGIOGENESIS INHIBITOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; STAT5 PROTEIN; VASCULOTROPIN A;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER MORTALITY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 7; ENDOMETRIUM; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ERYTHROID CELL; ERYTHROPOIESIS; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HEMATOPOIESIS; HUMAN; HYPOXIA; LUNG CANCER; LYMPHOMA; MYELOMA; NEUROPROTECTION; NONHUMAN; OVARY; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; SURVIVAL RATE; TRAUMATIC BRAIN INJURY; TUMOR GROWTH; VASODILATATION;

EID: 84865964648     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394310-1.00005-9     Document Type: Chapter

References (196)

1. Acs G., Acs P., Beckwith S.M., Pitts R.L., Clements E., Wong K., Verma A. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001, 61:3561-3565.
2. Acs G., Zhang P.J., McGrath C.M., Acs P., McBroom J., Mohyeldin A., Liu S., Lu H., Verma A. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am. J. Pathol. 2003, 162:1789-1806.
3. Acs G., Zhang P.J., Rebbeck T.R., Acs P., Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002, 95:969-981.
4. Ahn A., Frishman W.H., Gutwein A., Passeri J., Nelson M. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease: Part II. Cardiol. Rev. 2008, 16:219-229.
5. Anagnostou A., Lee E.S., Kessimian N., Levinson R., Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl Acad. Sci. USA. 1990, 87:5978-5982.
6. Anagnostou A., Liu Z., Steiner M., Chin K., Lee E.S., Kessimian N., Noguchi C.T. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA 1994, 91:3974-3978.
7. Arcasoy M.O., Amin K., Karayal A.F., Chou S.C., Raleigh J.A., Varia M.A., Haroon Z.A. Functional significance of erythropoietin receptor expression in breast cancer. Lab. Invest. 2002, 82:911-918.
8. Ashley R.A., Dubuque S.H., Dvorak B., Woodward S.S., Williams S.K., Kling P.J. Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatr. Res. 2002, 51:472-478.
9. Bahlmann F.H., De Groot K., Spandau J.M., Landry A.L., Hertel B., Duckert T., Boehm S.M., Menne J., Haller H., Fliser D. Erythropoietin regulates endothelial progenitor cells. Blood 2004, 103:921-926.
10. Barandon L., Couffinhal T., Dufourcq P., Ezan J., Costet P., Daret D., Deville C., Duplàa C. Frizzled A, a novel angiogenic factor: promises for cardiac repair. Eur. J. Cardiothorac. Surg. 2004, 25:76-83.
11. Batra S., Perelman N., Luck L.R., Shimada H., Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab. Invest. 2003, 83:1477-1487.
12. Bernaudin M., Marti H.H., Roussel S., Divoux D., Nouvelot A., Mackenzie E.T., Petit E. A potential role of erytropoietin in focal permanent cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 1999, 19:643-651.
13. Bikfalvi A., Han Z.C. Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia 1994, 8:523-529.
14. Blackwell K.L., Kirkpatrick J.P., Snyder S.A., Broadwater G., Farrell F., Jolliffe L., Brizel D.M., Dewhirst M.W. Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res. 2003, 63:6162-6165.
15. Bonsdorff E., Jalavisto E. A humoral mechanism in anoxic erythrocytosis. Acta Physiol. Scand. 1948, 16:150-170.
16. Boodhwani M., Sodha N.R., Laham R.J., Sellke F.W. The future of therapeutic myocardial angiogenesis. Shock 2006, 26:332-341.
17. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl Acad. Sci. USA 2000, 97:10526-10531.
18. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distants metastases in human soft tissue sarcoma. Cancer Res. 1996, 56:941-943.
19. Brunner S., Winogradow J., Huber B.C., Zaruba M.M., Fischer R., David R., Assmann G., Herbach N., Wanke R., Mueller-Hoecker J., Franz W.M. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXRC-4/SDF-1 axis. FASEB J. 2009, 23:351-361.
20. Buemi M., Cavallaio E., Floccari F., Sturiale A., Aloisi C., Trimarchi M., Corica F., Frisina N. The pleiotropic effects of erythropoietin in the central nervous system. J. Neuropathol. Exp. Neurol. 2003, 62:228-236.
21. Bunworasate U., Arnouk H., Minderman H., O'Loughlin K.L., Sait S.N., Barcos M., Stewart C.C., Baer M.R. Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood 2001, 98:3492-3494.
22. Bussolino F., Wang J.M., Defilippi P., Turrini F., Sanavio F., Edgell C.J., Aglietta M., Arese P., Mantovani A. Granulocyte and granulocyte-macrophage colony stimulating factor induce human endothelial cells to migrate and proliferate. Nature 1989, 337:471-473.
23. Calvillo L., Latini R., Kajstura J., Leri A., Anversa P., Grezzi P., Salio M., Cerami A., Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl Acad. Sci. USA 2003, 100:4802-4806.
24. Carlini R.G., Dusso A.S., Obialo C.I., Alvarez U.M., Rothstein M. Recombinant human erythropoietin (rHuEpo) increases endothelin-1 release by endothelial cells. Kidney Int. 1993, 43:1010-1015.
25. Carlini R.G., Reyes A.A., Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 1995, 55:546-553.
26. Carnot P., Deflandre C. Sur l'activité hémopoiétique du serum au cours de la régénération du sang. C. R. Acad. Sci. Paris 1906, 143:384-386.
27. Caro J.J., Salas M., Ward A., Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001, 91:2214-2221.
28. Chen H., Treweeke A.T., West D.C., Till K.J., Cawley J.C., Zuzel M., Toh C.H. In vitro and in vivo production of vascular endothelial growth factor in chronic lymphocytic leukemia cells. Blood 2000, 96:3181-3187.
29. Chikuma M., Masuda S., Kobayashi T., Nagao M., Sasaki R. Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am. J. Physiol. 2000, 279:E1242-E1248.
30. Chin K., Yu X., Beleslin-Cokic B., Liu C., Shen K., Mohrenweiser H.W., Noguchi C.M. Production and processing of erythropoietin receptor transcripts in brain. Mol. Brain Res. 2000, 81:29-42.
31. Chong Z.Z., Kang J.Q., Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002, 106:2973-2979.
32. Chong Z.Z., Kang J.Q., Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J. Cereb. Blood Flow Metab. 2003, 23:320-330.
33. Conrad K.P., Benyo D.F., Westerhausen-Larsen A., Miles T.M. Expression of erythropoietin by the human placenta. FASEB J. 1996, 10:760-768.
34. D'Andrea A.D., Zon L.I. Erythropoietin receptor. Subunit structure and activation. J. Clin. Invest. 1990, 86:681-687.
35. De Palma M., Venneri M.A., Roca C., Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 2003, 9:789-795.
36. Donnini S., Ziche M. Constitutive and inducible nitric oxide synthase: role in angiogenesis. Antioxid. Redox. Signal. 2002, 4:817-823.
37. Dunlop E.A., Maxwell A.P., Lappin T.R. Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma. Stem Cells 2007, 25:380-384.
38. Ebert B.L., Bunn H.F. Regulation of the erythropoietin gene. Blood 1999, 94:1864-1877.
39. Elliott S., Busse L., Bass M.B., Lu H., Sarosi I., Sinclair A.M., Spahr C., Um M., Van G., Begley C.G. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006, 107:1892-1895.
40. Elliott S., Busse L., McCAffery I., Rossi J., Sinclair A., Spahr C., Swift S., Begley C.G. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J. Immunol. Methods 2010, 352:126-139.
41. Erslev A.J. Humoral regulation of red cell production. Blood 1953, 8:349-357.
42. Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W. Correction of the anemia of end-stage disease with recombinant human erythropoietin. N. Engl. J. Med. 1987, 316:73-78.
43. Fairchil D., Benyo D., Conrad K.P. Expression of the erythropoietin receptor by trophoblast cells in the human placenta. Biol. Reprod. 1999, 60:861-870.
44. Fenjves E.S., Ochoa M.S., Cabrera O., Mendez A.J., Kenyon N.S., Inverardi L., Ricordi C. Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors. Transplantation 2003, 75:1356-1360.
45. Ferrario E., Ferrari L., Bidoli P., De Candii D., Del Vecchio M., De Dosso S., Buzzoni R., Bajetta E. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat. Rev. 2004, 30:563-575.
46. Fisher J.W., Birdwell B.J. The production of an erythropoietic factor by in situ perfused kidney. Acta Haematol. 1961, 26:224-232.
47. Fodinger M., Fritsche-Polanz R., Buchmayer H., Skoupy S., Sengoelge G., Horl W.H., Sunder-Plassman G. Erythropoietin-inducible immediate-early genes in human vascular endothelial cells. J. Investig. Med. 2000, 48:137-149.
48. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
49. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med. 1995, 1:27-31.
50. Fried W., Barone-Varelas J., Berman M. Detection of high erythropoietin titers in renal extracts of hypoxic rats. J. Lab. Clin. Med. 1981, 97:82-86.
51. Gewirtz D.A., Di X., Walker T.D., Sawyer S.T. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin. Cancer Res. 2006, 12:2232-2238.
52. Goldwasser E., Kung C.K.H. Progress in the purification of erythropoietin. Ann. N.Y. Acad. Sci. 1968, 149:49-53.
53. Groopman J.E., Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl Cancer Inst. 1999, 91:1616-1634.
54. Gurney C.W., Goldwasser E., Pan C. Studies on erythropoiesis. VI. Erythropoietin in human plasma. J. Lab. Clin. Med. 1957, 50:534-542.
55. Hamed S., Barshack I., Luboshits G., Wexler D., Deutsch V., Keren G.G., George J. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur. Heart J. 2006, 27:1876-1883.
56. Hardee M.E., Cao Y., Fu P., Jiang X., Zhao Y., Rabbani Z.N., Vujaskovic Z., Dewhirst M.W., Arcasoy M.O. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2007, 2:e549.
57. Heba G., Krzemiński T., Porc M., Grzyb J., Dembińska-Kieć A. Relation between expression of TNF alpha, iNOS, VEGF mRNA and development of heart failure after experimental myocardial infarction in rats. J. Physiol. Pharmacol. 2001, 52:39-52.
58. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., Mildner-Rihm C., Martin H., Zeihler A.M., Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102:1340-1346.
59. Henke M., Laszig R., Rübe C., Schäfer U., Haase K.D., Schilcher B., Mose S., Beer K.T., Burger U., Dougherty C., Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362:1255-1260.
60. Hirata A., Minamino T., Asanuma H., Sanada S., Fujita M., Tsukamoto O., Wakeno M., Myoishi M., Okada K., Koyama H., Konamura K.K., Takashima S., Shinozaki Y., Mori H., Tomoike H., Hori M., Kitakaze M. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc. Drugs Ther. 2005, 19:33-40.
61. Hirata A., Minamino T., Asanuma H., Fujita M., Wakeno M., Myoishi M., Tsukamoto O., Okada K., Koyama H., Konamura K.K., Takashima S., Shinozaki Y., Mori H., Shiraga M., Kitakaze M., Hori M. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J. Am. Coll. Cardiol. 2006, 48:176-184.
62. Hjorte E. Reticulocyte increase after injection of anemic serum. Norsk. Mag. F. Laegevidensk. 1936, 97:270-277.
63. Isner J.M., Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest. 1999, 103:1231-1236.
64. Jacobs C., Hörl W.H., Macdougall I.C., Valderrábano F., Parrondo I., Abraham I.L., Segner A. European best practice guidelines 9-13: anaemia management. Nephrol. Dial. Transplant. 2000, 15(S4):33-42.
65. Jacobs K., Shoemaker C., Rudersdorf R., Neill S.D., Kaufman R.J., Mufson A., Seehra J., Jones S.S., Hewick R., Fritsch E.F., Kawakita M., Shimizu T., Miyake T. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985, 313:806-810.
66. Jacobson L.O., Goldwaser E., Fried W., Plazk L. Role of kidney in erythropoiesis. Nature 1957, 179:633-634.
67. Jaquet K., Krause K., Tawakol-Khodai M., Geidel S., Kuck K.H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 2002, 64:326-333.
68. Jelkmann W. Effects of erythropoietin on brain function. Curr. Pharm. Biotechnol. 2005, 6:65-79.
69. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol. Rev. 1992, 72:449-489.
70. Jelkmann W., Bauer C. Demonstration of high levels of erythropoietin in rat kidneys following hypoxic hypoxia. Pflugers Arch. 1981, 392:34-39.
71. Juneja V., Keegan P., Gootenberg J.E., Rothmann M.D., Shen Y.L., Lee K.Y., Weiss K.D., Pazdur R. Continuing reassessment of the risk of erythropoiesis-stimulating agents in patients with cancer. Clin. Cancer Res. 2008, 14:3242-3247.
72. Juul S.E., Anderson D.K., Li Y., Christensen R.D. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr. Res. 1998, 43:40-49.
73. Juul S.E., Ledbetter D.J., Joyce A.E., Dame C., Christensen R.D., Zhao Y., De Marco V. Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 2001, 49:182-189.
74. Kawachi K., Iso Y., Sato T., Wakabayashi K., Kobayashi Y., Takeyama Y., Suzuki H. Effects of erythropoietin on angiogenesis after myocardial infarction in porcine. Heart Vessels 2012, 27:79-88.
75. Kayser K., Gabius H.J. Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand. Zentralbl. Pathol. 1992, 138:266-270.
76. Kertesz N., Wu J., Chen T.H.P., Sucov H.M., Wu H. The role of erythropoietin in regulating angiogenesis. Dev. Biol. 2004, 276:101-110.
77. Kling P.J., Sullivan T.M., Roberts R.A., Phillips A.F., Koldovsky O. Human milk as a potential enteral source of erythropoietin. Pediatr. Res. 1998, 43:216-221.
78. Kobayashi T., Yanase H., Iwanaga T., Sasaki R., Nagao M. Epididymis is a novel site of erythropoietin production in mouse reproductive organs. Biochem. Biophys. Res. Commun. 2002, 296:145-151.
79. Kokhaei P., Abdalla A.O., Hansson L., Mikaelsson E., Kubbies M., Haselbeck A., Jernberg-Wiklund H., Mellstedt H., Osterborg A. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin. Cancer Res. 2007, 13:3536-3544.
80. Koury S.T., Bondurant M.C., Koury M.J., Semenza G.L. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991, 77:2497-2503.
81. Krantz S.B., Goldwasser E. Specific binding of erythropoietin to spleen cells infected with the anemia strain of friend virus. Proc. Natl. Acad. Sci. USA 1984, 81:7574-7578.
82. Krieg M., Marti H.H., Plate K.H. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 1998, 92:3388-3393.
83. Krumdieck N. Erythropoietic substance in the serum of anemic animals. Proc. Soc. Exp. Biol. 1943, 54:14-17.
84. Krupinski J., Kaluza J., Kumar P., Kumar S., Wang J.M. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 1994, 25:1794-1798.
85. Kumar S.M., Acs G., Fang D., Herlyn M., Elder D.E., Xu X. Functional erythropoietin autocrine loop in melanoma. Am. J. Pathol. 2005, 166:823-830.
86. Kumar S.M., Zhang G., Bastian B.C., Arcasoy M.O., Karande P., Pushparajan A., Acs G., Xu X. Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene 2012, 31:1649-1660.
87. Kuratowska Z., Lewartowski B., Michalak E. Studies on the production of erythropoietin by isolated perfused organs. Blood 1961, 18:527-534.
88. Lacombe C., Mateux P. Biology of erythropoietin. Haematologica 1998, 83:724-732.
89. Lamontagne K.R., Butler J., Marshall D.J., Tullai J., Gechtman Z., Hall C., Meshaw A., Farrell F.X. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol. Cancer Ther. 2006, 5:347-355.
90. Leo C., Horn L.C., Rauscher C., Hentschel B., Liebmann A., Hildebrandt G., Höckel M. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin. Cancer Res. 2006, 12:6894-6900.
91. Lester R.D., Jo M., Campana W.M., Gonias S.L. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J. Biol. Chem. 2005, 280:39273-39277.
92. Leyland-Jones B., Semiglazov V., Pawlicki M., Pienkowski T., Tjulandin S., Manikhas G., Makhson A., Roth A., Dodwell D., Baselga J., Biakhov M., Valuckas K., Voznyi E., Liu X., Vercammen E. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 2005, 23:5960-5972.
93. Li J., Brown L.F., Hibberd M.G., Grossman J.D., Morgan J.P., Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am. J. Physiol. 1996, 270:H1803-H1811.
94. Lin C.S., Lim S.K., D'Agati V., Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev. 1996, 10:154-164.
95. Lin F.K., Suggs S., Lin C.H., Browne J.K., Smalling R., Egrie J.C., Chen K.K., Fox G.M., Martin F., Stabinsky Z., et al. Cloning and expression of the human erythropoietin gene. Proc. Natl Acad. Sci. USA 1985, 82:7580-7584.
96. Liu W.T., Powels T., Shamash J., Propper D., Oliver T., Joel S. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 2004, 23:981-990.
97. Magnanti M., Gandini O., Giuliani I., Gazzaniga P., Marti H.H., Gradilone A., Frati L., Aglianò A.M. Erythropoietin expression in primary rat Sertoli and peritubular myoid cells. Blood 2008, 98:2872-2874.
98. Mancuso P., Burlini A., Pruneti G., Goldhirirsch A., Martinelli G., Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001, 97:3658-3661.
99. 2+ channels: activation by phospholipase C-γ1. Kidney Int. 1998, 53:1259-1268.
100. Masuda S., Kobayashi T., Chikuma M., Nagao M., Sasaki R. The oviduct produces erythropoietin in an estrogen- and oxygen-dependent manner. Am. J. Physiol. Endocrinol. Metab. 2000, 278:E1038-E1044.
101. Masuda S., Nagao M., Takahata K., Konishi Y., Gallyas F., Tabira T., Sasaki R. Functional erythropoietin receptor of the cells with neural characteristics: comparison with receptor properties of erythroid cells. J. Biol. Chem. 1993, 268:11208-11216.
102. Masuda S., Okano K., Yamagishi M., Nagao M., Ueda M., Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J. Biol. Chem. 1994, 269:19488-19493.
103. Maxwell P.H., Ferguson D.J., Osmond M.K., Pugh C.W., Heryet A., Doe B.G., Johnson M.H., Ratcliffe P.J. Expression of a homologously recombined erythropoietin-SV40 T antigen fusion gene in mouse liver: evidence for erythropoietin production by Ito cells. Blood 1994, 84:1823-1830.
104. Maxwell P.H., Osmond M.K., Pugh C.W., Heryet A., Nicholls L.G., Tan C.C., Doe B.G., Ferguson D.J., Johnson M.H., Ratcliffe P.J. Identification of the renal erythropoietin producing cells using transgenic mice. Kidney Int. 1993, 44:1149-1162.
105. McCaffrey P.J., Fraser J.K., Lin F.K., Berridge M.V. Subunit structure of the erythropoietin receptor. J. Biol. Chem. 1989, 264:10507-10512.
106. Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D., Spivak J.L. Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. 1990, 322:1689-1692.
107. Mittelman M., Neumann D., Peled A., Kanter P., Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc. Natl Acad. Sci. USA 2001, 98:5181-5186.
108. Miyake T., Kung C.K., Goldwasser E. Purification of human erythropoietin. J. Biol. Chem. 1977, 252:5558-5564.
109. Monestiroli S., Mancuso P., Burlini A., Pruneti G., Dell'Agnola G., Gobbi A., Martinelli G., Bertolini F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001, 61:4341-4344.
110. Morita M., Ohneda O., Yamashita T., Takahashi S., Suzuki N., Nakajima O., Kawauchi S., Ema M., Shibahara S., Udono T., Tomita K., Tamai M., Sogawa K., Yamamoto M., Fujii-Kuriyama Y. HLF/HIF-2α is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 2003, 22:1134-1146.
111. Moritz K.M., Lim G.B., Wintour E.M. Developmental regulation of erythropoietin and erythropoiesis. Am. J. Physiol. 1997, 273R:1829-1881.
112. Moroni E., Dell'Era P., Rusnati M., Presta M. Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. J. Hematother. Stem Cell Res. 2002, 11:19-32.
113. Moura O., Nakamura N., Quelle F.W., Witthuhn B.A., Ihle J.N., Aoki N. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vitro. Blood 1994, 84:1501-1507.
114. Nakamatsu K., Nishimura Y., Suzuki M., Kanamori S., Maenishi P., Yasuda Y. Erythropoietin/erythropoietin-receptor system as an angiogenic factor in chemically induced hepatic tumors. Int. J. Clin. Oncol. 2004, 9:184-188.
115. Nakamura R., Takahashi A., Yamada T., Miyai N., Irie H., Kinoshita N., Sawada T., Azuma A., Matsubara H. Erythropoietin in patients with acute coronary syndrome and its cardioprotective action after percutaneous coronary intervention. Circ. J. 2009, 73:1920-1922.
116. Nakano M., Satoh K., Fukumoto Y., Ito Y., Kagaya Y., Ishii N., Sugamura K., Shimokawa H. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ. Res. 2007, 100:662-669.
117. Nelson M.A., Passeri J., Frishman W.H. Therapeutic angiogenesis: a new treatment modality for ischemic heart disease. Heart Dis. 2000, 2:314-325.
118. Nico B., Annese T., Guidolin D., Finato N., Crivellato E., Ribatti D. Epo is involved in angiogenesis in human glioma. J. Neurooncol. 2011, 102:51-58.
119. Nishiya D., Omura T., Shimada K., Matsumoto R., Kusuyama T., Enomoto S., Iwao H., Takeuchi K., Yoshikawa J., Yoshiyama M. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J. Pharmacol. Sci. 2006, 101:31-39.
120. Ogilvie M., Yu X., Nicolas-Metral V., Pulido S.M., Liu C., Ruegg U.T., Noguchi C.T. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J. Biol. Chem. 2000, 275:39754-39761.
121. Okazaki T., Ebihara S., Asada M., Yamanda S., Niu K., Arai H. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 2008, 10:932-939.
122. Oliva G., Chiuni F., Tramontana C. On the humoral regulation of the normoerythropoiesis. Acta Med. Scand. 1949, 133:27-30.
123. Olujohungbe A., Handa S., Holmes J. Does erythropoietin accelerate malignant transformation in multiple myeloma?. Postgrad. Med. J. 1997, 73:163-164.
124. Orlic D., Kajstura J., Chimenti S., Limana F., Jakoniuk I., Quaini F., Nadal-Ginard B., Bodine D.M., Leri A., Anversa P. Mobilized bone marrow cells repair myocardial infarcts in mice. Proc. Natl Acad. Sci. USA 2001, 98:10344-10349.
125. Oztürk M., Ustek D., Akbas F., Kösem M., Abaci N., Alagöl F., Oztürk G., Kotan C. The presence of erythropoietin receptor in parathyroid cells. J. Endocrinol. Invest. 2007, 30:RC35-RC37.
126. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., Thompson R.B., Petrofski J.A., Annex B.H., Stamoler J.S., Koch W.J. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 2003, 112:999-1007.
127. Pelletier L., Regnard J., Fellmann A., Chabord P. An in vitro model for the study of human bone marrow angiogenesis: role of hematopoietic cytokine. Lab. Invest. 2000, 80:501-511.
128. Perelman N., Selvaraj S.K., Batra S., Luck L.R., Erdreich-Epstein A., Coates T.D., Kalra V.K., Malik P. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood 2003, 102:1506-1514.
129. Pola R., Ling L.E., Silver M., Corbley M.J., Kearney M., Blake Pepinsky R., Shapiro R., Taylor F.R., Baker D.P., Asahara T., Isner J.M. The morphogen sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat. Med. 2001, 7:706-711.
130. Prunier F., Pfister O., Hadri L., Liang L., Del Monte F., Liao R., Hajjar R.J. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilize endothelial progenitor cells. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H522-H529.
131. Reissmann K.R. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood 1950, 5:372-380.
132. Reynolds L.P., Killilea S.D., Readmer D.A. Angiogenesis in the female reproductive system. FASEB J. 1992, 6:886-892.
133. Ribatti D. A potential role of erythropoietin in angiogenesis associated with myelodysplastic syndromes. Leukemia 2002, 16:1890.
134. Ribatti D. Hemangioblasts does exist. Leuk. Res. 2008, 32:850-854.
135. Ribatti D. The discovery of progenitor endothelial cells. Leuk. Res. 2007, 31:439-444.
136. Ribatti D. Angiogenic activity of classical hematopoietic cytokines. Leuk Res. 2012, 36:537-543.
137. Ribatti D., Conconi M.T., Nussdorfer G.G. Non classic endogenous novel regulators of angiogenesis. Pharmacol. Rev. 2007, 59:185-205.
138. Ribatti D., Marzullo A., Gentile A., Longo V., Nico B., Vacca A., Dammacco F. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 2007, 50:591-596.
139. Ribatti D., Marzullo A., Nico B., Crivellato E., Ria R., Vacca A. Erythropoietin is an angiogenic factor in gastric carcinoma. Histopathology 2003, 42:246-250.
140. Ribatti D., Nico B., Perra M.T., Longo V., Maxia C., Annese T., Piras F., Murtas D., Sirigu P. Erythropoietin is involved in angiogenesis in human primary melanoma. Int. J. Exp. Pathol. 2010, 91:495-499.
141. Ribatti D., Poliani P.L., Longo V., Manieri D., Nico B., Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 2007, 50:636-641.
142. Ribatti D., Presta M., Vacca A., Ria R., Giuliani R., Dell'Era P., Nico B., Roncali L., Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999, 93:2627-2636.
143. Ribatti D., Vacca A. Angiogenesis and anti-angiogenesis in haematological diseases. Magazine Eur. Med. Oncol. 2008, 1:31-33.
144. Ribatti D., Vacca A., Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999, 1:293-302.
145. Ribatti D., Vacca A., Roccaro A.M., Crivellato E., Presta M. Erythropoietin as an angiogenic factor. Eur. J. Clin. Invest. 2003, 33:891-896.
146. Ruhenstroth-Bauer G. Versuche zum Nachweis eines spezifischen erythropoietischen Hormines. Arch. Exp. Pathol. Pharmacol. 1950, 211:32-56.
147. Sakanaka M., Wen T.C., Matsuda S., Masuda S., Morishita E., Nagao M., Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl Acad. Sci. USA 1998, 95:4635-4640.
148. Sander G. Uber die Blutbildende Wir Kung des Serums von Tieren, die in verdunnnter Luft gehalten wurden. Zeitsch. Ges. Exp. Med. 1932, 82:633-646.
149. Schmid R., Gilbertsen A.S. Fundamental observations on the production of compensatory polycythemia in a case of patent ductus arteriosus with reversed blood flow. Blood 1955, 10:247-251.
150. Schuster S.J., Wilson J.H., Erslev A.J., Caro J. Physiologic regulation and tissue localization of renal erythropoietin messenger RNA. Blood 1987, 70:316-318.
151. Semenza G.L. Hypoxia, clonal selection and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 2000, 35:71-103.
152. Sereno M., Garcia-Cabezas M.A., De Castro J., Cejas P., Saenz E.C., Belda-Iniesta C., Feijoo J.B., Larrauri J., Nistal M., Baron M.G. Immunohistochemical expression of p53, Bcl-2, COX-2, C-erb-B2, EPO-R, beta-catenin, and E-cadherin in non tumoral gastric mucous membrane. Eur. J. Histochem. 2006, 50:285-292.
153. Shingo T., Sorakan S.T., Shimazaki T., Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J. Neurosci. 2001, 21:9733-9743.
154. Silva M., Grillot D., Benito A., Richard C., Nunez G., Fernandez-Luna J.L. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996, 88:1576-1582.
155. Sinclair A.M., Coxon A., McCaffery I., Kaufman S., Paweletz K., Liu L., Busse L., Swift S., Elliott S., Glenn Begley C. Functional erythropoietin is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010, 115:4264-4272.
156. Siren A.L., Knerlich F., Poser W., Gleiter C.H., Bruck W., Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. 2001, 101:271-276.
157. Soldi R., Primo L., Brizzi M.F., Sanavio F., Aglietta M., Polentarutti N., Pegoraro L., Mantovani A., Bussolino F. Activation of JAK2 in human vascular endothelial cells by granulocyte-macrophage colony stimulating factor. Blood 1997, 89:863-872.
158. Stohlman F., Rath C.E., Rose J.C. Evidence for a humoral regulation of erythropoiesis. Blood 1954, 9:721-733.
159. Sugimachi K., Tanaka S., Taguchi K., Aishima S., Shimada M., Tsuneyoshi M. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J. Clin. Pathol. 2003, 56:854-860.
160. Swift S., Ellison A.R., Kassner P., McCaffery I., Rossi J., Sinclair A.M., Begley C.G., Elliott S. Absence of functional EpoR expression in human tumor cell lines. Blood 2010, 115:4254-4263.
161. Takakura N., Huang X.L., Naruse T., Hamaguchi I., Dumont D.J., Yancopoulos G.D., Suda T. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity 1998, 9:677-686.
162. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994, 13:139-168.
163. Tilbrook P.A., Klinken S.P. Erythropoietin and erythropoietin receptor. Growth Factors 1999, 17:25-35.
164. Toma C., Letts D.P., Tanabe M., Gorcsan J., Counihan P.J. Positive effects of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion. J. Cell. Mol. Cardiol. 2007, 43:130-136.
165. Tóvári J., Gilly R., Rásó E., Paku S., Bereczky B., Varga N., Vágó A., Tímár J. Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res. 2005, 65:7186-7193.
166. Tsukada T., Eguchi K., Migita K., Kawabe Y., Nagataki S. Signal transduction of granulocyte macrophage stimulating factor in human endothelium-derived cell line. Tohoku J. Exp. Med. 1997, 183:185-194.
167. Uchida E., Morimoto K., Kawasaki N., Izaki Y., Abdu Said A., Hayahawa T. Effect of active oxygen radicals on protein and carbohydrate moieties of recombinant human erythropoietin. Free Radic. Res. 1997, 27:311-323.
168. Ueda K., Takano H., Nitsuma Y., Hasegawa H., Uchiyama R., Oka T., Miyazaki M., Nakaya H., Komuro I. Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J. Clin. Invest. 2010, 120:2016-2029.
169. Valdembri D., Serini A., Vacca A., Ribatti D., Bussolino F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J. 2002, 16:225-227.
170. Van der Meer P., Lipsic E., Henning R.H., Boddeus K., van der Velden J., Voos A.A., van Veldhuisen D.J., van Gilst W.H., Schoemaker R.G. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol. 2005, 46:125-133.
171. Vogel V., Kramer H.J., Backer A., Meyer-Lehnert H., Jelkmann W., Fandrey J. Effects of erythropoietin on endothelin-1 synthesis and cellular calcium messenger system in vascular endothelial cells. Am. J. Hypertens 1997, 10:289-297.
172. Vogt C., Pentz S., Rich I.N. A role for the macrophage in normal erythropoiesis: III. In vitro and in vivo erythropoietin gene expression in macrophages detected by in situ hybridization. Exp. Hematol. 1989, 17:391-397.
173. Wang L., Zhang Z., Wang Y., Zhang R., Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004, 35:1732-1737.
174. Wang X.Q., Vaziri N.D. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999, 33:894-899.
175. Wei L., Erinjeri J.P., Rovainen C.M., Woolsey T.A. Collateral growth and angiogenesis around cortical stroke. Stroke 2001, 32:2179-2184.
176. Westenbrink B.D., Lipsic E., van der Meer P., van der Harst P., Oeseburg H., Du Marchie Sarvaas G.J., Koster J., Voors A.A., van VVeldhuisen D.J., van Gilst W.H., Schoemaker R.G. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur. Heart J. 2007, 28:2018-2027.
177. Westenbrink B.D., Ruifrok W.P., Voors A.A., Tilton R.G., van Veldhuisen D.J., Schoemaker R.G., van Gilst W.H., de Boer R.A. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovasc. Res. 2010, 87:30-39.
178. Westenfelder C., Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000, 58:647-657.
179. Winearls C.G., Oliver D.O., Pippard M.J., Reid C., Downing M.R., Corest P.M. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet 1986, 2:1175-1178.
180. Winter S.C., Shah K.A., Campo L., Turley H., Leek R., Corbridge R.J., Cox G.J., Harris A.L. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Clin. Cancer Res. 2005, 11:7614-7620.
181. Witthuhn B.A., Quelle F.W., Silvennoinen O., Yi T., Tang B., Miura O., Ihle J.N. JAK-2 associates with erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993, 74:227-236.
182. Wojchowski D.M., Gregory R.C., Miller C.P., Pandit A.K., Pircher T.J. Signal transduction in the erythropoietin receptor system. Exp. Cell Res. 1999, 253:143-156.
183. Wright J.R., Ung Y.C., Julian J.A., Pritchard K.I., Whelan T.J., Smith C., Szechtman B., Roa W., Mulroy L., Rudinskas L., Gagnon B., Okawara G.S., Levine M.N. Randomized, double-blind, placebo-controlled trial or erythropoietin in non-small-cell lung cancer with disease-related anemia. J. Clin. Oncol. 2007, 25:1027-1032.
184. Wu H., Lee S.H., Gao J., Liu X., Iruela-Arispe M.L. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999, 126:3597-3605.
185. Wu H., Liu X., Jaenisch R., Lodish H.F. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995, 83:59-67.
186. Xue Y., Lim S., Yang Y., Wang Z., Jensen L.D.E., Hedlund E.M., Andersson P., Sasahara M., Larsson O., Galter D., Cao R., Hosaka K., Cao Y. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat. Med. 2012, 18:100-111.
187. Yamaji R., Okada T., Moriya M., Naito M., Tsuruo T., Miyatake K., Nakano Y. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur. J. Biochem. 1996, 239:494-500.
188. Yamazaki T., Kanzaki M., Kamidono S., Fujisawa M. Effects of erythropoietin on Leydig cell is associated with the activation of Stat5 pathway. Mol. Cell Endocrinol. 2004, 213:193-198.
189. Yang J., Xiao Z., Li T., Giu X., Fan B. Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis. Int. J. Oncol. 2012, 40:1230-1237.
190. Yasuda Y., Fujita Y., Masuda S., Musha T., Ueda K., Tanaka H., Fujita H., Matsuo T., Nagao M., Sasaki R., Nakamura Y. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002, 23:1797-1805.
191. Yasuda Y., Fujita Y., Musha T., Tanaka H., Shiokawa S., Nakamatsu K., Mori S., Matsuo T., Nakamura Y. Expression of erythropoietin in human female reproductive organs. Ital. J. Anat. Embryol. 2001, 106(Suppl. 2):215-222.
192. Yasuda Y., Masuda S., Chikuma M., Inoue K., Nagao M., Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J. Biol. Chem. 1998, 273:25381-25387.
193. Yasuda Y., Musha T., Tanaka H., Fujita Y., Fujita H., Utsumi H., Matsuo T., Masuda S., Nagao M., Sasaki R., Nakamura Y. Inhibition of erythropoietin signaling destroys xenografts of ovarian and uterine cancers in nude mice. Br. J. Cancer 2001, 84:836-843.
194. Yasuda Y., Fujita Y., Matsuo T., Koinuma S., Hara S., Tazaki A., Onozaki M., Hashimoto M., Musha T., Ogawa K., Fujita H., Nakamura Y., Shiozaki H., Utsumi H. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003, 24:1021-1029.
195. Yu X., Shacka J.J., Eells J.B., Suarez-Quian C., Przygodzki R.M., Beleslin-Cokic B., Lin C.S., Nikodem V.M., Hempstead B., Flanders K.C., Costantini F., Noguchi C.T. Erythropoietin receptor signalling is required for normal brain development. Development 2002, 129:505-516.
196. Zhao T., Zhao W., Chen Y., Ahokas R.A., Sun Y. Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction. Microvasc. Res. 2010, 80:188-194.